3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Head & Neck
1
Gynecologic
1
Conditions
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Diseases
1
Interventions
pembrolizumab
166
Carboplatin
132
Cisplatin
81
Paclitaxel
78
Gemcitabine
77
Pemetrexed
72
Bevacizumab
63
Docetaxel
54
Fluorouracil
49
Oxaliplatin
48
Dexamethasone
46
durvalumab
43
atezolizumab
39
Leucovorin
39
130-nm albumin-bound paclitaxel
39
Capecitabine
37
Cetuximab
36
Rituximab
35
Nivolumab
35
Fulvestrant
35
Cyclophosphamide
34
Injections
31
venetoclax
29
Prednisone
28
Lenalidomide
28
enzalutamide
27
pomalidomide
25
Letrozole
25
Irinotecan
25
daratumumab
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Imlunestrant
×
30 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled
NCT07287098
2026-05-22
preEMBER
Eli Lilly and Company
Phase 2
Not yet recruiting
600 enrolled